Halozyme Therapeutics, Inc.
HALO
$74.93
$1.532.08%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.18B | 1.08B | 1.02B | 947.36M | 873.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.18B | 1.08B | 1.02B | 947.36M | 873.30M |
| Cost of Revenue | 228.37M | 221.62M | 201.66M | 212.80M | 217.06M |
| Gross Profit | 950.30M | 862.69M | 813.66M | 734.56M | 656.25M |
| SG&A Expenses | 167.47M | 161.56M | 154.34M | 149.69M | 143.72M |
| Depreciation & Amortization | 71.05M | 71.05M | 71.05M | 71.05M | 71.13M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 496.00M | 486.84M | 463.85M | 470.35M | 468.71M |
| Operating Income | 682.67M | 597.47M | 551.48M | 477.01M | 404.59M |
| Income Before Tax | 692.13M | 604.93M | 557.13M | 480.09M | 416.71M |
| Income Tax Expenses | 134.85M | 119.57M | 113.04M | 87.63M | 79.41M |
| Earnings from Continuing Operations | 557.28 | 485.36 | 444.09 | 392.47 | 337.29 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 557.28M | 485.36M | 444.09M | 392.47M | 337.29M |
| EBIT | 682.67M | 597.47M | 551.48M | 477.01M | 404.59M |
| EBITDA | 758.60M | 673.22M | 627.09M | 553.00M | 480.80M |
| EPS Basic | 4.48 | 3.86 | 3.50 | 3.08 | 2.62 |
| Normalized Basic EPS | 3.46 | 2.98 | 2.72 | 2.33 | 1.95 |
| EPS Diluted | 4.37 | 3.76 | 3.43 | 3.02 | 2.58 |
| Normalized Diluted EPS | 3.38 | 2.92 | 2.67 | 2.29 | 1.92 |
| Average Basic Shares Outstanding | 497.81M | 503.59M | 507.31M | 509.96M | 515.08M |
| Average Diluted Shares Outstanding | 509.92M | 514.98M | 517.22M | 519.28M | 523.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |